Leerink Partners Maintains Outperform on Travere Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an 'Outperform' rating on Travere Therapeutics and raised the price target from $20 to $40, indicating a positive outlook for the company's stock.
October 11, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has raised the price target for Travere Therapeutics from $20 to $40 while maintaining an 'Outperform' rating, suggesting a positive short-term outlook for the stock.
The increase in price target from $20 to $40 by Leerink Partners, along with the maintained 'Outperform' rating, indicates strong confidence in Travere Therapeutics' future performance. This is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100